22.55
Precedente Chiudi:
$22.70
Aprire:
$22.975
Volume 24 ore:
4.86M
Relative Volume:
1.02
Capitalizzazione di mercato:
$11.27B
Reddito:
$4.89B
Utile/perdita netta:
$-242.00M
Rapporto P/E:
-46.11
EPS:
-0.489
Flusso di cassa netto:
$315.00M
1 W Prestazione:
+0.00%
1M Prestazione:
+0.53%
6M Prestazione:
-0.27%
1 anno Prestazione:
+4.30%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Inc
|
22.55 | 11.27B | 4.89B | -242.00M | 315.00M | -0.489 |
|
TAK
Takeda Pharmaceutical Co Adr
|
19.93 | 63.67B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.62 | 47.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.02 | 44.06B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
79.62 | 32.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
563.49 | 24.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-20 | Downgrade | Jefferies | Buy → Hold |
| 2026-10-16 | Iniziato | Goldman | Buy |
| 2026-04-15 | Iniziato | Citigroup | Buy |
| 2026-01-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
Timothy J. Bettington Disposes 4,350 Shares of Elanco Animal Health Stock at $23 Each on October 15, 2026 - Kalkine Media
At $23 each, Elanco (ELAN) officer Bettington sells 4,350 shares under a trading plan. - Stock Titan
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Officer Timothy J. Bettington proposes selling 4,350 shares of Elanco Animal Health (ELAN). - Stock Titan
Dwight Evans Stock Trades and Disclosures - TechGraph
An executive at Elanco (ELAN) acquires 66.7087 stock-linked units at $22.14 each. - Stock Titan
At $22.14 each, Elanco (ELAN) CFO acquires 8.8988 units payable in shares or cash. - Stock Titan
A 127.6843-unit stock grant brings Elanco (ELAN) CEO's holdings to 25,499.2826 stock-linked units. - Stock Titan
Deferring cash fees, Elanco (ELAN) director Kapila K. Anand acquires 642 stock-linked units. - stocktitan.net
Elanco Animal Health CEO Jeffrey N. Simmons Reports Acquisition of Deferred Stock Units - Kalkine Media
Form 4 Elanco Animal Health For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Elanco Animal Health For: 22 September By Investing.com - Investing.com Canada
Elanco Animal Health (ELAN) CEO adds 126 deferred stock units - Stock Titan
Elanco (NYSE: ELAN) exec adds 65.8756 deferred stock units - Stock Titan
Elanco (NYSE: ELAN) CFO now holds 158.6535 deferred stock units - Stock Titan
Elanco Animal Health Incorporated (ELAN) Latest Press Releases & Corporate News - finance.yahoo.com
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement - Yahoo Finance
Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - PR Newswire
Elanco Animal Health (ELAN) CFO receives 8 deferred stock units - Stock Titan
Deferred stock award lifts Elanco Animal Health (NYSE: ELAN) exec's holdings - Stock Titan
Elanco (NYSE: ELAN) CEO adds to deferred pay with new stock grant - Stock Titan
Elanco Animal Health (ELAN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Mutts With a Mission: How Elanco and Medical Mutts Transform Lives Together - CSRwire
Elanco Animal Health Stock Price Forecast. Should You Buy ELAN? - StockInvest.us
Elanco Director Purchases 40,000 Shares for $936,000 - Yahoo Finance
Elanco Director Purchases 40,000 Shares for $936,000 - The Motley Fool
Elanco Animal Health Inc (ELAN) Stock Price, Quote, News & History - Benzinga
Is Elanco Animal Health Inc (ELAN) Overvalued After 3.2% Rally? - GuruFocus
Pharma clinical research firm eyes former Elanco building in Greenfield - Indianapolis Business Journal
Elanco Animal Health (ELAN) Institutional Ownership 2026 $ELAN - MarketBeat
Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility - marketscreener.com
Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility - finance.yahoo.com
Elanco Animal Health (ELAN) Stock Analysis: Unveiling a 29% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Elanco Says Demand for Its New Dog Treatment Is Twice What Was Expected - Stock Titan
Elanco (NYSE: ELAN) EVP now holds 9,770 deferred units - Stock Titan
Elanco Animal Health CEO Jeffrey N. Simmons Acquires 117.94 Deferred Stock Units - kalkinemedia.com
Elanco (NYSE: ELAN) reports new insider share trade - Stock Titan
Elanco (NYSE: ELAN) CFO holds 141.8242 deferred stock units - Stock Titan
Elanco Animal Health CFO Robert M. VanHimbergen Acquires 8.22 Deferred Stock Units - Kalkine Media
US Insider Trades Show Shifts In Key Names - TradingPedia
Top insider buys and sells disclosed on Friday - Investing.com
Top insider buys and sells disclosed on Friday By Investing.com - Investing.com South Africa
Elanco Animal Health (ELAN) Stock Analysis: Unlocking a 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Elanco Animal Health (NYSE:ELAN) Director Lawrence Erik Kurzius Purchases 40,000 Shares - MarketBeat
Elanco director Kurzius buys $935,920 in company stock - Investing.com
Elanco director Kurzius buys $935,920 in company stock - Investing.com
Elanco Animal Health Director Purchased Shares Worth Over $935K - TradingView
Elanco (NYSE: ELAN) director buys 40K shares, stake now 188,647 - Stock Titan
Danske Bank A S Makes New $14.35 Million Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Shares Fall 3.8% -- What GF Scor - GuruFocus
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Elanco Animal Health Inc Azioni (ELAN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bettington Timothy J | Officer |
Oct 15 '26 |
Proposed Sale |
23.00 |
4,350 |
100,050 |
0 |
| Kurzius Lawrence Erik | Director |
Aug 20 '26 |
Buy |
23.40 |
40,000 |
935,920 |
188,647 |
| O'Neill Shiv | GC AND CORP SEC |
Aug 18 '26 |
Buy |
23.58 |
3,998 |
94,273 |
87,832 |
| Harrington Michael J | Director |
Aug 12 '26 |
Buy |
21.82 |
5,000 |
109,100 |
131,451 |
| Herendeen Paul | Director |
Aug 07 '26 |
Buy |
23.68 |
10,000 |
236,850 |
111,687 |
| VanHimbergen Robert M | EVP and CFO |
Aug 07 '26 |
Buy |
23.08 |
4,200 |
96,926 |
137,516 |
| Modi Rajeev A. | SEE REMARKS |
May 15 '26 |
Buy |
20.35 |
4,911 |
99,939 |
160,812 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
May 15 '26 |
Buy |
20.09 |
4,971 |
99,843 |
171,971 |
| Kurzius Lawrence Erik | Director |
Dec 12 '25 |
Buy |
21.30 |
10,000 |
213,000 |
131,773 |
| Modi Rajeev A. | SEE REMARKS |
Dec 11 '25 |
Buy |
21.33 |
4,500 |
95,985 |
123,082 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):